Filana Therapeutics (FLNA) Research & Development (2010 - 2026)

Filana Therapeutics has reported Research & Development for 15 years, with the latest figure at $3.3 million in Q2 2026.

• On a quarterly basis, Research & Development fell 35.44% year-over-year to $3.3 million in Q2 2026; TTM through Jun 2026 was $15.7 million, a 72.53% decrease from a year earlier, with the FY2025 full-year figure at $26.6 million, down 61.82% from the prior year.
• Research & Development was $3.3 million for Q2 2026 at Filana Therapeutics, down from $4.5 million in the prior quarter.
• The five-year high for Research & Development was $25.0 million in Q2 2023, with the low at $3.3 million in Q2 2026.
• Average Research & Development over 5 years is $14.4 million, with a median of $16.9 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Research & Development gained 27.4% in 2023, then plunged 81.23% in 2025.
• Over 5 years, Research & Development stood at $17.7 million in 2022, then climbed by 6.11% to $18.7 million in 2023, then rose by 9.6% to $20.5 million in 2024, then slumped by 81.23% to $3.9 million in 2025, then decreased by 14.27% to $3.3 million in 2026.
• The last three Research & Development figures came in at $3.3 million (Q2 2026), $4.5 million (Q1 2026), and $3.9 million (Q4 2025), per Business Quant data.